Physician profile
Jana Phillips
NPI 1477714731
$8,269.81
in general payments reported to CMS, 2019-2025
45 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $452 · 2021: $139 · 2022: $922 · 2023: $1,016 · 2024: $1,546 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,539 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.87 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,154.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $810.89 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $624.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $611.64 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $595.89 | 2019-2024 | Breztri, Airsupra |
| Abbott Laboratories | $506.80 | 2022-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.19 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $361.92 | 2021-2025 | |
| Abbvie INC. | $304.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $295.63 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $251.20 | 2019-2024 | |
| Dexcom, INC. | $237.76 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $165.23 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.38 | 2019-2021 | |
| Radius Health, INC. | $141.83 | 2019-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $121.47 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $120.05 | 2019-2025 | Capvaxive |
| Valeritas, INC. | $111.09 | 2019 | |
| Esperion Therapeutics, INC. | $109.56 | 2024-2025 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $102.03 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $101.59 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $98.03 | 2025 | Twiist |
| Pfizer INC. | $96.63 | 2022-2024 | |
| Insulet Corporation | $88.66 | 2019 | |
| Amryt Pharma Holdings LTD | $75.31 | 2023 | Mycapssa |
| Medtronic, INC. | $73.66 | 2022-2025 | Intellis Adaptivestim, Minimed 780g |
| Shire North American Group INC | $55.36 | 2019 | |
| Ascendis Pharma Endocrinology INC | $53.56 | 2023-2025 | Yorvipath |
| Regeneron Healthcare Solutions, INC. | $45.62 | 2019 | |
| Recordati_rare_diseases_inc. | $38.91 | 2023 | Signifor Lar, Isturisa |
| Madrigal Pharmaceuticals | $38.03 | 2025 | Rezdiffra |
| Cequr Corporation | $33.17 | 2024 | Cequr Simplicity |
| Averitas Pharma INC. | $29.49 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $28.39 | 2025 | Strensiq |
| Neurocrine Biosciences, INC. | $26.01 | 2024 | |
| Halozyme INC | $22.70 | 2023 | |
| Ascensia Diabetes Care US INC. | $21.62 | 2025 | |
| Chiesi USA, INC. | $21.12 | 2024 | Mycapssa |
| Kyowa Kirin, INC. | $19.53 | 2024 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $18.97 | 2025 | Imcivree |
| Ibsa Pharma INC. | $17.31 | 2024 | Tirosint, Licart |
| Acella Pharmaceuticals, LLC | $14.61 | 2025 | NP Thyroid 60 |
| Horizon Therapeutics Plc | $13.61 | 2023 | Tepezza |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jana Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.